WAITING, WAITING AND MORE WAITING WHILE ALL IS QUIET ON THE NBS FRONT.
Should it really take until mid-November for the PreSERVE AMR-01 results to be known? I very much doubt that. Why is there this waiting? Is NBS shopping the results for a partnership? When will BAX announce the results of its P3 RENEW study using PCT cells? If BAX already knows the results of the RENEW study as seems likely is it currently in discussions with NBS?
Let’s not forget either the Belgian Federal Agency for Medicines and Health Products (FAMHP) Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 being conducted by Cardio3 Biosciences in Belgium? Nor should we forget the VSEL studies for radiation exposure. What are their results?
Soon we can expect the filing of an IND following positive PreRESERVE results being published for the preservation of heart function following an AMI. Then there would be enrollment presumably for a P1b/2a study for CHF, the start of a P2 trial for Type I diabetes using Tregs, the start of a P1b/2a trial for steroid resistant asthma using Tregs, the start of a Meta-T P3 trial for melanoma, and God knows what other trials lingering in the minds of management. Any one of these studies would benefit from a partnership in order to fast track a start. Any partnership would probably mirror the CBMG guidelines wherein the partner would pay for study costs except for licensing fees. Meanwhile there will be further demand for PCT's contract development and manufacturing services.
The Aspire Capital financing of up to 30 million even with the 41 million cash probably less estimated to be on the books already will not be enough to finance all the trials that are planned. Nor will another secondary offering following the announcement of good news leading to a rise in pps probably fill the financing hunger impinging upon fertile management imaginations.
The more time that passes increases the likelihood of the announcement of a critical partnership. NBS simply has too much on its plate to continue doing its thing alone much longer. It is not a question of IF there will be a partnership announced but WHEN.
The Gamida Cell purchase by Novartis for 600 million put small cap stem cell companies like NBS in play and a buyout offer remains a definite possibility especially from BAX. The AEGIS projection of a pps of 21 is entirely possible within a year.
